You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 10, 2024

Claims for Patent: 5,545,405

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,545,405

Title:	Method for treating a mammal suffering from cancer with a cho-glycosylated antibody
Abstract:	The invention relates to a CHO cell-line capable of producing antibody, the cell-line having been co-transfected with a vector capable of expressing the light chain of the antibody and a vector capable of expressing the heavy chain of the antibody wherein the vectors contain independently selectable markers; also included is a CHO cell-line capable of producing a human antibody or an altered antibody, the cell-line having been transfected with a vector capable of expressing the light chain of the antibody and the heavy chain of the antibody; process for the production of antibody using a CHO cell-line and antibody having CHO glycosylation.
Inventor(s):	Page; Martin J. (Beckenham, GB)
Assignee:	Burroughs Wellcome Co. (Research Triangle Park, NC)
Application Number:	08/335,401
Patent Claims:	1. In a method for treating a human suffering from cancer by administering a therapeutically effective amount of a whole glycosylated recombinant human, chimeric, CDR grafted or bispecific antibody effective in treating said cancer, wherein the improvement comprises an antibody glycosylated by a Chinese hamster ovary cell. 2. A method in accordance with claim 1, wherein the cancer is non-Hodgkins lymphoma. 3. A method in accordance with claim 1, wherein the cancer is multiple myeloma. 4. A method in accordance with claim 3, wherein the antibody specifically recognizes a T cell marker. 5. A method in accordance with claim 4, wherein the antibody is an anti-CDw52 antibody. 6. A method in accordance with claim 1, wherein the antibody specifically recognizes a cancer cell marker antigen. 7. A method in accordance with claim 6, wherein the antibody is an anti-CD33 antibody or an anti-CD38 antibody. 8. A method in accordance with claim 1, wherein the antibody is administered in a daily dose of about 1 mg to about 10 mg. 9. A method in accordance with claim 1, wherein the antibody is administered for a period of about 1 to about 30 days.

Details for Patent 5,545,405

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	05/07/2001	⤷ Try a Trial	2013-08-13
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	11/14/2014	⤷ Try a Trial	2013-08-13
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	10/12/2004	⤷ Try a Trial	2013-08-13
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 5,545,405

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
South Africa	918248	⤷ Try a Trial
United States of America	5545404	⤷ Try a Trial
United States of America	5545403	⤷ Try a Trial
United States of America	2008279852	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.